News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Registration is open for Part III of the AORTIC North America Series
Nov 30, 2024, 16:39

Registration is open for Part III of the AORTIC North America Series

AORTIC Africa shared a post on LinkedIn:

“Have you registered for Part III of the AORTIC North America Series yet? Hosted by the Dana-Farber Cancer Institute. Not to be missed! See below the QR code to register.”

Registration is open for Part III of the AORTIC North America Series

More posts featuring AORTIC Africa.

AORTIC Africa AORTIC North America Series cancer Dana-Farber Cancer Institute OncoDaily Oncology
Special Coverage
Blog
Nov 30, 2024, 16:55
A message from YouTube’s former CEO Susan Wojcicki - American Cancer Society
Insight
Nov 30, 2024, 16:49
Raymond Chan: Fixing our eyes and "actions" to make a difference through our research and education
Blog
Nov 30, 2024, 16:44
Celebrating the 30th Anniversary of Childhood Cancer International
Blog
Nov 30, 2024, 16:39
Registration is open for Part III of the AORTIC North America Series
Blog
Nov 30, 2024, 16:34
Training and innovation in oncology at the PALOP VI Conference - AORTIC Africa
Drugs
Nov 30, 2024, 16:22
Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC
Insight
Nov 30, 2024, 16:17
Vivek Subbiah: The development of immunotherapy in MSI-H and D-MMR cancers by Thierry Andre et al.
Blog
Nov 30, 2024, 16:13
Maria Navarro: Adapting WHO’s GBCI framework to Cali’s unique context
Blog
Nov 30, 2024, 16:08
Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients
Blog
Nov 30, 2024, 16:06
Tedros Adhanom Ghebreyesus: Meeting with Foreign and Trade Minister Péter Szijjártó
Blog
Nov 30, 2024, 16:01
IL-15 to enhance the effectiveness of GPC3-targeting CAR T cells in solid tumors
Blog
Nov 30, 2024, 15:58
Dana-Farber - Changing how outcomes of clinical trials are shared with patients by publishing summaries of trials